MS Pharma Group, Hetero Group Partner to Localize Biosimilars in MENA Region

MS Pharma Group, a regional pharmaceutical company in the MENA region, has signed a strategic partnership agreement with Hetero Group, a global pharmaceutical company, to localize five established biosimilars across key therapeutic areas, including oncology, immunology and hematology.

The exclusive agreement will be implemented through El Kendi, MS Pharma Group’s affiliate in Algeria, and Hetero Biopharma, a subsidiary of Hetero Group. This marks Hetero’s first local partnership in the country, representing a significant step towards strengthening Algeria’s biopharmaceutical ecosystem. The combined portfolio represents an estimated total market value of $45 million in Algeria and will be executed through a localization and technology transfer approach.

“We are pleased to collaborate with a global partner like Hetero, with whom we share a long-term commitment to knowledge transfer and improving healthcare outcomes for patients in the region. This collaboration reflects MS Pharma Group’s ongoing commitment to expanding patient access to trusted and affordable biologic treatments, while supporting the sustainability and resilience of local healthcare systems,” said Kalle Känd, CEO of MS Pharma.

Dr. Vamsi Krishna, MD, Hetero Group, said, “We are pleased to enter into a strategic partnership with MS Pharma, a well-established and trusted healthcare leader in the Middle East and beyond. This collaboration marks an important step in advancing healthcare delivery and addressing unmet medical needs across the Middle East, Algeria, and other key markets.”